Moderna Inc. experienced a significant boost in its stock price, driven by promising developments in its cancer vaccine initiative and a return to the Nasdaq-100 index.
Moderna Inc. (NASDAQ:MRNA) went up yesterday by an impressive 14.21%, closing at CA$225.00. This surge was fueled by positive news surrounding its cancer vaccine program and its re-inclusion in the Nasdaq-100 index, which has reignited investor enthusiasm for the biotech company.
Advertisement
Moderna Inc
MRNA.US
MRNA.US
Moderna Inc
WealthAwesomeMarket cap
$89.83B
52W high
$225.00
52W low
$22.28
1W change
+18.41%
Beta
1.09
Analyst Price Targets
Based on 23 analysts covering MRNA · as of Oct 12, 2026
Wall Street analysts forecast MRNA stock price to fall 45.5% over the next 12 months.
Consensus
Hold3.17 / 5.00
Avg. Target
C$122.67
-45.5% Upside
Previously C$121.00 on Oct 8, 2026
Current Price
C$225.00
Last close
Analyst Breakdown (23 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MRNA's historical volatility
30-Day Vol
80.7%
Annualized
90-Day Vol
194.8%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$268.99
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$238.80 | C$180.76 – C$315.48 |
| 60 trading days | C$253.45 | C$170.95 – C$375.76 |
| 90 trading days | C$268.99 | C$166.06 – C$435.71 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors are optimistic about Moderna's future as it diversifies its portfolio beyond COVID-19 vaccines, particularly with its advancements in cancer treatment.
14.21%
Advertisement
Moderna's stock price jumped 14.21% yesterday, reflecting strong investor sentiment following recent developments in its cancer vaccine program.
Bull case
The recent success in clinical trials for its cancer vaccine, intismeran autogene, along with the company's return to the Nasdaq-100, suggests a strong growth trajectory and renewed investor confidence. Investors are excited about the potential of this vaccine, especially after the positive Phase 3 results for melanoma, which have positioned Moderna as a key player in cancer treatment.
Bear case
Despite the positive momentum, some concerns linger about whether Moderna's current valuation can hold up. Analysts point out that the company needs to generate significant revenue growth in oncology to justify its market price, especially given its ongoing losses. The market is closely watching how Moderna transitions from its COVID-19 vaccine focus to a more diversified portfolio.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
